BMY · Company research
6 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Milvexian (oral factor XIa inhibitor; BMS/Johnson & Johnson) for Secondary stroke prevention in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Cobenfy (xanomeline-trospium) for Alzheimer's disease psychosis (ADEPT-1) in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Bristol-Myers Squibb Company expects to report results from its Phase 3 study of milvexian for Stroke prevention in atrial fibrillation (LIBREXIA-AF) in Q1 2027 (Jan–Mar) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Cobenfy (xanomeline/trospium) for Psychosis associated with Alzheimer's disease (ADEPT-1/2/4) in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is due to decide by May 13, 2027 whether to approve Bristol-Myers Squibb Company’s mezigdomide for Relapsed or refractory multiple myeloma (SUCCESSOR-2). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Bristol-Myers Squibb Company expects to report results from its Phase 3 study of Milvexian (oral factor XIa inhibitor; BMS/Johnson & Johnson) for Stroke prevention in atrial fibrillation during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Bristol-Myers Squibb Company’s ZENBEXUS (iberdomide) for Relapsed/refractory multiple myeloma on Aug 13, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Bristol-Myers Squibb Company presented data on Camzyos (mavacamten) for Symptomatic obstructive hypertrophic cardiomyopathy in adolescents at a medical meeting on Mar 30, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Bristol-Myers Squibb Company’s Opdivo (nivolumab) + AVD for Previously untreated stage III/IV classical Hodgkin lymphoma on Mar 20, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to BMY.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.